BABahman Akbari

Bahman Akbari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bahman Akbari has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Fatemeh Safari

    Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran

    8 shared publications
  • Safar Farajnia

    Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

    8 shared publications
  • Shiva Ahdi Khosroshahi

    Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

    8 shared publications
  • Nejat Mahdieh

    Cardiogenetic Research Center, Rajaie Cardiovascular Medical and Research Institute, Iran University of Medical Sciences, Tehran, Iran

    7 shared publications
  • Leila Rahbarnia

    Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

    6 shared publications
  • Mohammad Reza Khirehgesh

    Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran

    5 shared publications

Latest Publications

  • Association of Obstructive Sleep Apnea Syndrome with Leptin Receptor Gene Q223R and K109R Single Nucleotide Polymorphisms in the Iranian Kurdish Population

    by Ali Alizadeh Severi, Sharareh Rasouli, Mohammad Abdolsamadi, Fatemeh Safari, Farhad Salari, Nejat Mahdieh, Kamal Veisi, Bahman Akbari

    Background: Obstructive sleep apnea syndrome (OSAS) is a kind of sleep disturbance in which breathing is reduced or stopped for a short time and, if left untreated, can lead to long-term dangerous complications such as heart attack and obesity. Previous studies have shown that leptin receptor (LEPR) gene polymorphisms correlate with obesity and OSAS. This study aimed to measure the correlation of LEPR K109R and Q223R gene polymorphisms with OSAS in the Kurd population of Kermanshah, Iran. Materials and Methods: This study's population includes 100 patients with OSAS and 100 healthy individuals. Polysomnography diagnostic tests were performed on both patient and control groups. Polymerase chain reaction-restriction fragment length polymorphism was used to check the association between OSAS and LEPR gene polymorphisms. Results: Significant differences were observed in the allelic frequencies and genotype distributions of the LEPR K109R single nucleotide polymorphism (SNP) between the patients with OSAS and those of the healthy controls, whereas no such differences were found in the allelic and genotype frequencies of LEPR gene Q223R polymorphism. Additionally, the genotypic distribution of patients did not correspond to the severity of the disease. Conclusion: The results indicate an association between K109R and OSAS, with no such relation between Q223R and OSAS. Neither of the SNPs showed a link with the disease severity level.

  • The Association Between the C-Reactive Protein Gene Variants rs1130864 and rs2794521 and Obstructive Sleep Apnea in the Iranian Kurdish Population

    by Sharareh Rasouli, Ali Alizadeh Severi, Mohammad Abdolsamadi, Yaser Mohassel, Fatemeh Safari, Farhad Salari, Nejat Mahdieh, Shiva Ahdi Khosroshahi, Bahman Akbari

    Introduction: Obstructive sleep apnea (OSA) syndrome is a widespread multifactorial disorder that raises the risk of cardiovascular disease, diabetes, and Alzheimer's disease. This study aimed to investigate the association between the risk of OSA and two C-reactive protein (CRP) gene variants, rs1130864 and rs2794521. Materials and methods: In this study, 100 patients and 100 controls participated. Among 500 patients with OSA attending the sleep disorder center, 100 were randomly selected from those with apnea/hypopnea symptoms and daytime sleepiness. Polymerase chain reaction and restriction fragment length polymorphism of the CRP gene polymorphisms were used in this investigation. Results: The frequency of the mutant C allele was higher in the patient group than in the control group for the rs2794521 CRP gene variant (p ≤ 0.001), and the C allele elevated the risk of OSA by 2.584 times (odds ratios = 2.584, 95% confidence interval). The frequency of the mutant T allele was higher in the patient group than in the control group for the rs1130864 CRP gene variant, while the frequency of the C allele was higher in the control group, and this difference was statistically significant (p ≤ 0.001). Conclusions: Our findings indicated that rs1130864 and rs2794521 of the CRP gene are associated with increased risk for OSA. Extensive research is required to determine the role of distinct CRP gene variants in OSA.


  • Open Access

    Pancreatitis as a Main Consequence of APOC2-Related Hypertriglyceridemia: The Role of Nonsense and Frameshift Variants

    by Bahareh Rabbani, Mohadeseh Aghli Moghadam, Shiva Esmaeili, Amirhassan Rabbani, Bahman Akbari, Nejat Mahdieh

    APOC2-related hypertriglyceridemia occurs due to biallelic variants of this gene. Here, genotype-phenotype architecture of all pathogenic APOC2 variants is investigated among heterozygous and homozygous individuals. Clinical heterogeneity of various types of the variants is also described, and pancreatitis in more than half of homozygotes carrying chain-termination variants is highlighted as well. For this study, patients were selected who had a plasma triglyceride level above 250mg/dL. The coding and intronic regions of the APOC2 gene were amplified using the Sanger sequencing to investigate the presence of variants. The genotypes, lipid profiles, and detailed clinical features were documented for all APOC2-related patients and heterozygous individuals. Pathogenicity of the variants was predicted and categorized using available bioinformatics tools such as MutationTaster and PolyPhen-2 and ACMG criteria. MetaDome and Phyre2 were applied for structural and functional in silico analyses. 40 (12 out of 30) of APOC2 variants were chain-termination (nonsense and frameshift) variants. These types of variants were determined in 60.53 of patients. 55 of these patients showed pancreatitis followed by lipemia retinalis (29), abdominal pain (24), hepatosplenomegaly (24), and xanthomas (18). The mean age of onset was about 22 years old. In at least 50 of 38 homozygous individuals, the TG level was more than 2000mg/dL. More than 25 of heterozygous individuals showed at least one symptom. Pancreatitis and a severe form of HTG were found in 5 and 2 of heterozygous individuals, respectively. The main clinical features of APOC2-related hypertriglyceridemia include pancreatitis, lipemia retinalis, abdominal pain, hepatosplenomegaly, and xanthomas. Nonsense and frameshift homozygous variants usually lead to a severe form of hypertriglyceridemia. Pancreatitis is one of the main consequences of these types of mutations; thus, it is important to consider this point when evaluating asymptomatic individuals. Heterozygous individuals may become symptomatic due to the role of unknown modifying agent including environmental genetic factors.


  • CRISPR‐Cas9 delivery strategies and applications: Review and update

    by Ali Alizadeh Severi, Bahman Akbari

    Summary: Nowadays, a significant part of the investigations carried out in the medical field belong to cancer treatment. Generally, conventional cancer treatments, including chemotherapy, radiotherapy, and surgery, which have been used for a long time, are not sufficient, especially in malignant cancers. Because genetic mutations cause cancers, researchers are trying to treat these diseases using genetic engineering tools. One of them is clustered regularly interspaced short palindromic repeats (CRISPR), a powerful tool in genetic engineering in the last decade. CRISPR, which forms the CRISPR‐Cas structure with its endonuclease protein, Cas, is known as a part of the immune system (adaptive immunity) in bacteria and archaea. Among the types of Cas proteins, Cas9 endonuclease has been used in many scientific studies due to its high accuracy and efficiency. This review reviews the CRISPR system, focusing on the history, classification, delivery methods, applications, new generations, and challenges of CRISPR‐Cas9 technology.


  • The Association Between the 5-Hydroxytryptamine Receptor 2A Gene Variants rs6311 and rs6313 and Obstructive Sleep Apnea in the Iranian Kurdish Population

    by Mohammad Abdolsamadi, Sharareh Rasouli, Ali Alizadeh Severi, Mohammad Reza Khirehgesh, Fatemeh Safari, Nejat Mahdieh, Habibolah Khazaie, Bijan Soleymani, Bahman Akbari

    Introduction: Sleep is one of the most significant parts of everyone's life. Most people sleep for about one-third of their lives. Sleep disorders negatively impact the quality of life. Obstructive sleep apnea (OSA) is a severe sleep disorder that significantly impacts the patient's life and their family members. This study aimed to investigate the relationship between rs6313 and rs6311 polymorphisms in the serotonin receptor type 2A gene and OSA in the Kurdish population. Materials and Methods: The study's population comprises 100 OSA sufferers and 100 healthy people. Polysomnography diagnostic tests were done on both the patient and control groups. The polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) was used to investigate the relationship between OSA and LEPR gene polymorphisms. Results: Statistical analysis showed a significant relationship between genotype frequencies of patient and control groups of rs6311 with OSA in dominant [odds ratio (OR) = 5.203, p < 0.001) and codominant models (OR = 9.7, p < 0.001). Also, there was a significant relationship between genotype frequencies of patient and control groups of rs6313 with OSA in dominant (OR = 10.565, p < 0.001) and codominant models (OR = 5.938, p < 0.001). Conclusions: Findings from the study demonstrated that the two polymorphisms rs6311 and rs6313 could be effective at causing OSA; however, there was no correlation between the severity of the disease and either of the two polymorphisms.


  • Improvement of 5-fluorouracil chemosensitivity in colorectal cancer cells by siRNA-mediated silencing of STAT6 oncogene

    by Omid Rahbar Farzam, Behzad Baradaran, Bahman Akbari, Souzan Najafi, Mohammad Amini, Amirhossein Yari, Reza Dabbaghipour, Vahid Pourabdollah Kaleybar, Shiva Ahdi Khosroshahi

    Objective(s): Colorectal cancer (CRC) remains a major health concern worldwide due to its high incidence, mortality rate, and resistance to conventional treatments. The discovery of new targets for cancer therapy is essential to improve the survival of CRC patients. Here, this study aims to present a finding that identifies the STAT6 oncogene as a potent therapeutic target for CRC. Materials and Methods: HT-29 CRC cells were transfected with STAT6 siRNA and treated with 5-fluorouracil (5-FU) alone and combined. Then, to evaluate cellular proliferation and apoptosis percentage, MTT assay and annexin V/PI staining were carried out, respectively. Moreover, the migration ability of HT-29 cells was followed using a wound-healing assay, and a colony formation assay was performed to explore cell stemness features. Gene expression was quantified via qRT-PCR. Afterward, functional enrichment analysis was used to learn in-depth about the STAT6 co-expressed genes and the pathways to which they belong. Results: Our study shows that silencing STAT6 with small interfering RNA (siRNA) enhances the chemosensitivity of CRC cells to 5-FU, a commonly used chemotherapy drug, by inducing apoptosis, reducing proliferation, and inhibiting metastasis. These results suggest that combining 5-FU with STAT6-siRNA could provide a promising strategy for CRC treatment. Conclusion: Our study sheds light on the potential of STAT6 as a druggable target for CRC cancers, the findings offer hope for more effective treatments for CRC patients, especially those with advanced stages that are resistant to conventional therapies.

  • Open Access

    Interplay of miRNAs and lncRNAs in STAT3 signaling pathway in colorectal cancer progression

    by Omid Rahbar Farzam, Souzan Najafi, Mohammad Amini, Zohreh Rahimi, Reza Dabbaghipour, Omid Zohdi, Ghazale Asemani Shahgoli, Behzad Baradaran, Bahman Akbari

    In recent decades, colorectal cancer (CRC) has turned into one of the most widespread malignancies, and the incidence of this malignancy is expected to increase. Despite considerable improvements in therapeutic approaches, the prognosis, and the management of CRC face many problems. Likely, the main limitation in the successful treatment of CRC is the lack of appropriate clinical therapeutic targets. As an effective target, the signal transducer and activator of transcription 3 (STAT3) are regulated by a wide range of genes and involved in cellular processes, including cell growth, migration, invasion, immunosuppression, and angiogenesis. Aberrant regulation of STAT3 signaling leads to cellular dysfunction, diseases, and malignancies, including CRC. Consequently, targeting this signaling pathway is considered one of the therapeutic strategies used in CRC treatment. MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are non-coding RNA molecules with partial or no protein-coding activity that participate in gene regulation at epigenetic, transcriptional, and post-transcriptional levels and regulate multiple signaling pathways, including STAT3 signaling (especially JAK/STAT). Therefore, these regulatory molecules are suggested to be very promising targets to present new insights into overcoming the limitations of conventional therapeutic strategies. Therefore, the current review study aimed to summarize the therapeutic and diagnostic significance of miRNAs and lncRNAs and their therapeutic and diagnostic significance related to the expression and activity of STAT3 in CRC.


  • Open Access

    Improvement of 5-Fluorouracil Chemosensitivty In Colorectal Cancer Cells by siRNA-Mediated Silencing of STAT6 Oncogene

    by Omid Rahbar Farzam, Behzad Baradaran, Souzan Najafi, Mohammad Amini, Vahid Pourabdollah Kaleybar, Reza Dabbaghipour, Shiva Ahdi Khosroshahi, Bahman Akbari

    Background: One of the cancers that occur most frequently around the world is colorectal cancer (CRC). STAT6 transcription factor is involved in cellular multipotency, tumor cell growth, drug resistance, stemness, and migration, showing potential as a cancer therapy target for a variety of cancers, including CRC. In this regard, the current study aimed to investigate the effect of STAT6 silencing via small interference RNA (siRNA) in combination with 5-FU on CRC development. Methods: The MTT assay and the Annexin V/PI staining were used to examine cell proliferation and apoptosis induction, respectively. Flow cytometry was performed to investigate cell cycle progression. Wound healing assays were also used to examine HT-29 cell migration. A colony formation assay was used to examine cell stemness features of HT-29 cells. The qRT-PCR was used to measure the gene expression levels in the samples. Results: Apoptosis induction by STAT6 inhibition significantly improved the HT-29 cell chemosensitivity to 5-FU. Both caspase-9 apoptotic gene and Bax/Bcl-2 ratio were upregulated when STAT6 suppression and 5-FU were combined. Additionally, combination therapy led to cell cycle arrest at the sub-G1 phase in CRC cells. The combined therapy also significantly reduced MMP9 expression, which in turn reduced the migration of HT-29 cells. Furthermore, STAT6 knockdown inhibited HT-29 cell colony formation by reducing the expression of the Sox2 and CD44 genes, either alone or in combination with 5-FU. Conclusions: The findings show that combination therapy of 5-FU and STAT6 silencing may be an effective treatment for patients with CRC.

  • Design and construction a novel humanized biparatopic nanobody-based immunotoxin against epidermal growth factor receptor (EGFR)

    by Mohammad Reza Khirehgesh, Jafar Sharifi, Bahman Akbari, Kamran Mansouri, Fatemeh Safari, Bijan Soleymani, Kheirollah Yari